<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862106</url>
  </required_header>
  <id_info>
    <org_study_id>71006.01-2</org_study_id>
    <nct_id>NCT02862106</nct_id>
  </id_info>
  <brief_title>Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B</brief_title>
  <official_title>Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) in Treating Chronic Hepatitis B Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Jiachen Biotechnology Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chongqing Jiachen Biotechnology Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to evaluate efficacy and safety of therapeutic HBV vaccine (mimogen-based)
      treatment in chronic hepatitis B patients and to explore the most effective dosage and
      provide the rational for optimal dosing schedule.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Second stage(76-144 weeks):

      In this follow-up stage the trial is open designed, and all the subjects completed the first
      stage study(0-76 weeks)

        1. Subjects with virological response but no serological response/with serological response
           but no virological response/neither virological nor serological response in the first
           stage, and be willing to continue the this follow-up study, will be treated by εPA-44
           900 μg at week 80,83,86,89,92,95,98,101,104,108,112,116,120,124,128.

        2. Subjects with both virological and serological response, will be followed-up to 144
           weeks with no Adefovir Dipivoxil or εPA-44 900 μg treatment.

      The definition of response as below:

        1. Virological response: HBV DNA＜2.93×10∧3IU/ml at 76 weeks;

        2. Serological response: serological conversion of HBeAg at 76 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Patients About HBeAg / Anti-HBe Seroconversion at the End of the Follow-up Period</measure>
    <time_frame>Endpoint (LOCF), up to 144 weeks</time_frame>
    <description>Primary endpoint data were summarised under &quot;End of Study&quot;,using the last available post-baseline observation(Last Observation Carried Forward,LOCF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients About HBeAg / Anti-HBe Seroconversion at week95,108,120,144</measure>
    <time_frame>week95,108,120,144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients With Both Negative HBeAg and HBeAb.</measure>
    <time_frame>week95,108,120,144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients About HBsAg / Anti-HBs Seroconversion at Week 95,108,120,144</measure>
    <time_frame>week95,108,120,144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients With Both Negative HBsAg and HBsAb.</measure>
    <time_frame>week95,108,120,144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients With HBV DNA Levels Undetectable or Below the Detection Limit</measure>
    <time_frame>week95,108,120,144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline by Visit for Serum HBV DNA</measure>
    <time_frame>week95,108,120,144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved HBV DNA Levels &lt;29300 IU/mL or HBV DNA Load Decrease Equal or Greater Than 2 Log Scales;</measure>
    <time_frame>week95,108,120,144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline by Vsit for HBeAg Titer.</measure>
    <time_frame>week95,108,120,144</time_frame>
    <description>Measuring the change in value of each visit viewpoints HBeAg titers decreased compared with baseline values</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">209</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>εPA-44 900μg group-placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These subjects from the placebo group of protocol 71006.01 InjectεPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
  </arm_group>
  <arm_group>
    <arm_group_label>εPA-44 900μg group-εPA-44 600μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
  </arm_group>
  <arm_group>
    <arm_group_label>εPA-44 900μg group-εPA-44 900μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Follow-up group-placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Follow-up group-εPA-44 600μg</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Follow-up group-εPA-44 900μg</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>εPA-44</intervention_name>
    <description>subcutaneously injection of εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
    <arm_group_label>εPA-44 900μg group-placebo</arm_group_label>
    <arm_group_label>εPA-44 900μg group-εPA-44 600μg</arm_group_label>
    <arm_group_label>εPA-44 900μg group-εPA-44 900μg</arm_group_label>
    <other_name>Therapeutic HBV vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subjects completed the first stage study(0-76 weeks) and willing to willing to
             participate in the trial

          2. Uses effective contraception for subject with child-bearing potential (including
             females and female partners of males)

          3. Understands and signs ICF approved by EC

          4. Willing to comply with the study procedures and complete the study

        Exclusion Criteria:

        1.Any other factors inappropriate for enrollment in the study or study completion in the
        view of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lai Wei, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hepatitis Institute of Peking University People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renmin Hosptial of Wuhan University</name>
      <address>
        <city>WuHan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>ChangSha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>81th Hospital of PLA</name>
      <address>
        <city>NanJing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TangDu Hospital</name>
      <address>
        <city>XiAn</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>WenZhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302 Militray Hosptial of China</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepatitis Institute of Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital</name>
      <address>
        <city>ChongQing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2016</study_first_submitted>
  <study_first_submitted_qc>August 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2016</study_first_posted>
  <results_first_submitted>November 20, 2016</results_first_submitted>
  <results_first_submitted_qc>November 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2017</results_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>HBeAg positive</keyword>
  <keyword>Therapeutic HBV Vaccine</keyword>
  <keyword>HBV-specific Cytotoxic T Lymphocyte</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants completed the first stage(0-76weeks),enrolled at 9 sites in the China. The first participant was screened on 19 November 2011.</recruitment_details>
      <pre_assignment_details>209 participants entered the second stage of the study , and comprise the Safety Analysis Set and the Full Analysis Set</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>εPA-44 900μg</title>
          <description>Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
εPA-44: Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
        </group>
        <group group_id="P2">
          <title>Follow-up Group</title>
          <description>Do not give any intervention, follow-up observation only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subjects moved to other city</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety population</population>
      <group_list>
        <group group_id="B1">
          <title>Follow-up Group-placebo</title>
          <description>These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
        </group>
        <group group_id="B2">
          <title>Follow-up Group-εPA-44 600μg</title>
          <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
        </group>
        <group group_id="B3">
          <title>Follow-up Group-εPA-44 900μg</title>
          <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
        </group>
        <group group_id="B4">
          <title>εPA-44 900μg Group-placebo</title>
          <description>These subjects from the placebo group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
        </group>
        <group group_id="B5">
          <title>εPA-44 900μg Group-εPA-44 600μg</title>
          <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
        </group>
        <group group_id="B6">
          <title>εPA-44 900μg Group-εPA-44 900μg</title>
          <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="64"/>
            <count group_id="B5" value="56"/>
            <count group_id="B6" value="58"/>
            <count group_id="B7" value="203"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="56"/>
                    <measurement group_id="B6" value="58"/>
                    <measurement group_id="B7" value="203"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.7" spread="6.03"/>
                    <measurement group_id="B2" value="25.2" spread="4.39"/>
                    <measurement group_id="B3" value="25.8" spread="8.02"/>
                    <measurement group_id="B4" value="30.4" spread="7.56"/>
                    <measurement group_id="B5" value="29.6" spread="9.14"/>
                    <measurement group_id="B6" value="29.4" spread="7.61"/>
                    <measurement group_id="B7" value="29.4" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.69" spread="4.043"/>
                    <measurement group_id="B2" value="21.23" spread="2.181"/>
                    <measurement group_id="B3" value="21.42" spread="2.601"/>
                    <measurement group_id="B4" value="21.95" spread="2.615"/>
                    <measurement group_id="B5" value="21.76" spread="3.273"/>
                    <measurement group_id="B6" value="22.12" spread="2.792"/>
                    <measurement group_id="B7" value="21.89" spread="2.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Patients About HBeAg / Anti-HBe Seroconversion at the End of the Follow-up Period</title>
        <description>Primary endpoint data were summarised under &quot;End of Study&quot;,using the last available post-baseline observation(Last Observation Carried Forward,LOCF)</description>
        <time_frame>Endpoint (LOCF), up to 144 weeks</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-up Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O2">
            <title>Follow-up Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O3">
            <title>Follow-up Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O4">
            <title>εPA-44 900μg Group-placebo</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O5">
            <title>εPA-44 900μg Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O6">
            <title>εPA-44 900μg Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients About HBeAg / Anti-HBe Seroconversion at the End of the Follow-up Period</title>
          <description>Primary endpoint data were summarised under &quot;End of Study&quot;,using the last available post-baseline observation(Last Observation Carried Forward,LOCF)</description>
          <population>Intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="38.7"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients About HBeAg / Anti-HBe Seroconversion at week95,108,120,144</title>
        <time_frame>week95,108,120,144</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-up Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O2">
            <title>Follow-up Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O3">
            <title>Follow-up Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O4">
            <title>εPA-44 900μg Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O5">
            <title>εPA-44 900μg Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O6">
            <title>εPA-44 900μg Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients About HBeAg / Anti-HBe Seroconversion at week95,108,120,144</title>
          <population>Intention to treat population</population>
          <units>percentage of paricipant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="25.8"/>
                    <measurement group_id="O5" value="21.8"/>
                    <measurement group_id="O6" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="55.6"/>
                    <measurement group_id="O4" value="32.3"/>
                    <measurement group_id="O5" value="32.7"/>
                    <measurement group_id="O6" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="72.7"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="29.0"/>
                    <measurement group_id="O5" value="30.9"/>
                    <measurement group_id="O6" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="81.8"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="37.1"/>
                    <measurement group_id="O5" value="32.7"/>
                    <measurement group_id="O6" value="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients With Both Negative HBeAg and HBeAb.</title>
        <time_frame>week95,108,120,144</time_frame>
        <population>intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-up Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O2">
            <title>Follow-up Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O3">
            <title>Follow-up Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O4">
            <title>εPA-44 900μg Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O5">
            <title>εPA-44 900μg Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O6">
            <title>εPA-44 900μg Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With Both Negative HBeAg and HBeAb.</title>
          <population>intention to treat population</population>
          <units>percentage of paricipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.6"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3.2"/>
                    <measurement group_id="O5" value="3.6"/>
                    <measurement group_id="O6" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4.8"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4.8"/>
                    <measurement group_id="O5" value="3.6"/>
                    <measurement group_id="O6" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients About HBsAg / Anti-HBs Seroconversion at Week 95,108,120,144</title>
        <time_frame>week95,108,120,144</time_frame>
        <population>intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-up Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O2">
            <title>Follow-up Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O3">
            <title>Follow-up Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O4">
            <title>εPA-44 900μg Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O5">
            <title>εPA-44 900μg Group-εPA-44 600μg</title>
            <description>These subjects from theεPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O6">
            <title>εPA-44 900μg Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients About HBsAg / Anti-HBs Seroconversion at Week 95,108,120,144</title>
          <population>intention to treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients With Both Negative HBsAg and HBsAb.</title>
        <time_frame>week95,108,120,144</time_frame>
        <population>intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-up Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O2">
            <title>Follow-up Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O3">
            <title>Follow-up Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O4">
            <title>εPA-44 900μg Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O5">
            <title>εPA-44 900μg Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O6">
            <title>εPA-44 900μg Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With Both Negative HBsAg and HBsAb.</title>
          <population>intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients With HBV DNA Levels Undetectable or Below the Detection Limit</title>
        <time_frame>week95,108,120,144</time_frame>
        <population>intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-up Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O2">
            <title>Follow-up Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O3">
            <title>Follow-up Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O4">
            <title>εPA-44 900μg Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O5">
            <title>εPA-44 900μg Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O6">
            <title>εPA-44 900μg Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With HBV DNA Levels Undetectable or Below the Detection Limit</title>
          <population>intention to treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="90.9"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="25.8"/>
                    <measurement group_id="O5" value="30.9"/>
                    <measurement group_id="O6" value="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="90.9"/>
                    <measurement group_id="O3" value="55.6"/>
                    <measurement group_id="O4" value="33.9"/>
                    <measurement group_id="O5" value="25.5"/>
                    <measurement group_id="O6" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="63.6"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="32.3"/>
                    <measurement group_id="O5" value="23.6"/>
                    <measurement group_id="O6" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="63.6"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="35.5"/>
                    <measurement group_id="O5" value="30.9"/>
                    <measurement group_id="O6" value="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline by Visit for Serum HBV DNA</title>
        <time_frame>week95,108,120,144</time_frame>
        <population>intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-up Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O2">
            <title>Follow-up Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O3">
            <title>Follow-up Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O4">
            <title>εPA-44 900μg Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O5">
            <title>εPA-44 900μg Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O6">
            <title>εPA-44 900μg Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline by Visit for Serum HBV DNA</title>
          <population>intention to treat population</population>
          <units>log_10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline values of log</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="0.64"/>
                    <measurement group_id="O2" value="7.6" spread="0.97"/>
                    <measurement group_id="O3" value="7.5" spread="1.1"/>
                    <measurement group_id="O4" value="7.8" spread="0.88"/>
                    <measurement group_id="O5" value="8.1" spread="0.9"/>
                    <measurement group_id="O6" value="8.0" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 95 decreases from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="0.67"/>
                    <measurement group_id="O2" value="5.1" spread="1.23"/>
                    <measurement group_id="O3" value="5.6" spread="0.92"/>
                    <measurement group_id="O4" value="2.8" spread="1.83"/>
                    <measurement group_id="O5" value="2.7" spread="2.18"/>
                    <measurement group_id="O6" value="2.9" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 108 decreases from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="0.14"/>
                    <measurement group_id="O2" value="5.2" spread="1.24"/>
                    <measurement group_id="O3" value="5.4" spread="0.71"/>
                    <measurement group_id="O4" value="3.0" spread="2.10"/>
                    <measurement group_id="O5" value="3.1" spread="2.17"/>
                    <measurement group_id="O6" value="3.2" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 120 decreases from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="0.97"/>
                    <measurement group_id="O2" value="5.2" spread="0.99"/>
                    <measurement group_id="O3" value="5.9" spread="0.83"/>
                    <measurement group_id="O4" value="3.0" spread="2.19"/>
                    <measurement group_id="O5" value="3.3" spread="1.94"/>
                    <measurement group_id="O6" value="2.8" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 144 decreases from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="0.34"/>
                    <measurement group_id="O2" value="5.1" spread="1.09"/>
                    <measurement group_id="O3" value="5.6" spread="1.21"/>
                    <measurement group_id="O4" value="3.2" spread="2.27"/>
                    <measurement group_id="O5" value="4.1" spread="1.77"/>
                    <measurement group_id="O6" value="3.3" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved HBV DNA Levels &lt;29300 IU/mL or HBV DNA Load Decrease Equal or Greater Than 2 Log Scales;</title>
        <time_frame>week95,108,120,144</time_frame>
        <population>intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-up Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O2">
            <title>Follow-up Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O3">
            <title>Follow-up Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O4">
            <title>εPA-44 900μg Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O5">
            <title>εPA-44 900μg Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O6">
            <title>εPA-44 900μg Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved HBV DNA Levels &lt;29300 IU/mL or HBV DNA Load Decrease Equal or Greater Than 2 Log Scales;</title>
          <population>intent to treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="59.7"/>
                    <measurement group_id="O5" value="52.7"/>
                    <measurement group_id="O6" value="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="55.6"/>
                    <measurement group_id="O4" value="61.3"/>
                    <measurement group_id="O5" value="60.0"/>
                    <measurement group_id="O6" value="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="72.7"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="54.8"/>
                    <measurement group_id="O5" value="58.2"/>
                    <measurement group_id="O6" value="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="81.8"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="61.2"/>
                    <measurement group_id="O5" value="58.2"/>
                    <measurement group_id="O6" value="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline by Vsit for HBeAg Titer.</title>
        <description>Measuring the change in value of each visit viewpoints HBeAg titers decreased compared with baseline values</description>
        <time_frame>week95,108,120,144</time_frame>
        <population>intend to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-up Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O2">
            <title>Follow-up Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O3">
            <title>Follow-up Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only</description>
          </group>
          <group group_id="O4">
            <title>εPA-44 900μg Group-placebo</title>
            <description>These subjects from the placebo group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O5">
            <title>εPA-44 900μg Group-εPA-44 600μg</title>
            <description>These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
          <group group_id="O6">
            <title>εPA-44 900μg Group-εPA-44 900μg</title>
            <description>These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline by Vsit for HBeAg Titer.</title>
          <description>Measuring the change in value of each visit viewpoints HBeAg titers decreased compared with baseline values</description>
          <population>intend to treat population</population>
          <units>IU/ML</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline of HBeAg titers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1276.5" spread="1447.33"/>
                    <measurement group_id="O2" value="758.5" spread="1287.52"/>
                    <measurement group_id="O3" value="285.9" spread="411.9"/>
                    <measurement group_id="O4" value="681.9" spread="658.52"/>
                    <measurement group_id="O5" value="958.3" spread="929.45"/>
                    <measurement group_id="O6" value="880.9" spread="1368.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 95 decreases from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1276.3" spread="1447.33"/>
                    <measurement group_id="O2" value="-758.3" spread="1287.52"/>
                    <measurement group_id="O3" value="-285.7" spread="411.9"/>
                    <measurement group_id="O4" value="-435.8" spread="685.25"/>
                    <measurement group_id="O5" value="-617.1" spread="913.09"/>
                    <measurement group_id="O6" value="-550.7" spread="1834.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 108 decreases from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-446.3" spread="237.59"/>
                    <measurement group_id="O2" value="-758.3" spread="1287.52"/>
                    <measurement group_id="O3" value="-38.9" spread="49.73"/>
                    <measurement group_id="O4" value="-476.8" spread="728.21"/>
                    <measurement group_id="O5" value="-807.0" spread="1011.18"/>
                    <measurement group_id="O6" value="-602.9" spread="1755.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 120 decreases from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-446.3" spread="237.64"/>
                    <measurement group_id="O2" value="-979.9" spread="1463.54"/>
                    <measurement group_id="O3" value="-314.4" spread="576.36"/>
                    <measurement group_id="O4" value="-500.7" spread="654.06"/>
                    <measurement group_id="O5" value="-769.4" spread="1017.49"/>
                    <measurement group_id="O6" value="-486.3" spread="927.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 144 decreases from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-446.3" spread="237.59"/>
                    <measurement group_id="O2" value="-923.9" spread="1379.30"/>
                    <measurement group_id="O3" value="-285.7" spread="411.9"/>
                    <measurement group_id="O4" value="-546.3" spread="629.66"/>
                    <measurement group_id="O5" value="-788.4" spread="887.7"/>
                    <measurement group_id="O6" value="-691.5" spread="1708.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Follow-up Group</title>
          <description>Do not give any intervention, follow-up observation only All safety analyzes were analyzed in a safe population, and since 1 subjects had no safety data, they were excluded from the safety population</description>
        </group>
        <group group_id="E2">
          <title>εPA-44 900μg Group</title>
          <description>Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128 All safety analyzes were analyzed in a safe population, and since 5 subjects had no safety data, they were excluded from the safety population</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Severe chronic hepatitis B</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Acute exacerbation of Chronic hepatitis B</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Chronic nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mouth ulcers</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Gum pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Gingival swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Leukocytes in urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Elevated transaminase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators can't publish articles relevant to the study unless the sponsor permits.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Wu</name_or_title>
      <organization>Institute of Immunology，PLA</organization>
      <phone>02368752230 ext 86</phone>
      <email>wuyuzhang@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

